Premium
Molecular markers and targeted therapies for adrenocortical carcinoma
Author(s) -
Xu Yunze,
Qi Yicheng,
Zhu Yu,
Ning Guang,
Huang Yiran
Publication year - 2014
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/cen.12358
Subject(s) - adrenocortical carcinoma , medicine , disease , bioinformatics , targeted therapy , oncology , mechanism (biology) , mitotane , carcinogenesis , cancer research , cancer , biology , philosophy , epistemology
Summary Adrenocortical carcinoma ( ACC ) is a lethal disease with poor prognosis and lack of effective therapeutic options. Systemic treatment is often employed to treat patients with advanced ACC , but outcomes are disappointing. During the last decade, some of the causative genetic mutations in sporadic ACC s have been identified. Molecular analysis has had a significant impact on the understanding of the pathogenetic mechanism of ACC development and the evaluation of prognostic and predictive markers. Preclinical investigations and clinical trials of tyrosine kinase inhibitors and anti‐angiogenic compounds have been initiated to seek target therapy of ACC s. This review summarizes the current view of molecular alterations involved in the pathophysiology of adrenocortical carcinogenesis. The rationale for testing targeted therapies of ACC is also presented.